Najla Al Ali

Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes

Mrinal M. Patnaik, Eric Padron, Rebecca R. Laborde et al. · Leukemia · 2013 · 215 citations

Hematological Malignancy, Oncology, Engineering +12

Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation

Andrew Kuykendall, Savan Shah, Chetasi Talati et al. · Annals of Hematology · 2017 · 126 citations

Translational Medicine, Ruxolitinib Discontinuation, Hard Place +5

Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides

Amer M. Zeidan, Mikkael A. Sekeres, Guillermo Garcia‐Manero et al. · Leukemia · 2015 · 84 citations · Full text

Hematological Malignancy, Higher-risk Myelodysplastic Syndromes, Disease Risk Assessment +9

Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

David A. Sallman, Amy E. DeZern, Guillermo Garcia‐Manero et al. · Blood · 2019 · 73 citations

Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes

Anthony M. Hunter, Rami S. Komrokji, Seongseok Yun et al. · Blood Advances · 2021 · 71 citations · Full text

Mixed-phenotype Acute Leukemia, Genetic Epidemiology, Pathology +16